Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24157395 | 0.82 | BRPF1 (0.47) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL30212596 | 0.82 | BRPF1 (0.47) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL30212561 | 0.81 | BRPF1 (0.46) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL24156584 | 0.81 | BRPF1 (0.46) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL24157270 | 0.80 | PGR (0.34) | CREBBPPOLBBRD4PGR | |
| SCHEMBL14765170 | 0.78 | BRPF1 (0.44) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL31049730 | 0.77 | BRPF1 (0.42) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL25377725 | 0.77 | BRPF1 (0.42) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL14765190 | 0.77 | CREBBP (0.58) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL15243711 | 0.77 | CREBBP (0.58) | BRPF1CREBBPGSK3BPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059929-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122036686-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036687-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122010903-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4452256-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | Astrazeneca AB (SE) | 2024-10-30 | — | — | EP | disclosed |
| CN-118317793-A | Methods for treating brain tumors and neuroblastomas | 阿斯利康(瑞典)有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11795158-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2023-10-24 | — | — | US | disclosed |
| US-11795158-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2023-10-24 | — | — | US | disclosed |
| WO-2023118085-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118085-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2023-06-29 | — | — | WO | disclosed |
| EP-4172152-A1 | QUINOXALINE DERIVATIVES AS ANTI-CANCER DRUGS | Astrazeneca AB (SE) | 2023-05-03 | — | — | EP | disclosed |
| CN-115768760-A | Quinoxaline derivatives as anti-cancer agents | 阿斯利康(瑞典)有限公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2021260092-A1 | QUINOXALINE DERIVATIVES AS ANTI-CANCER DRUGS | ASTRAZENECA AB (SE) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795158-B2 | Chemical compounds | CYP11B2, CYP11B1, CYP4B1 | BRPF1 2632/4885CREBBP 1032/4885GSK3B 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.